清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)

作者
Timothy Francis Cloughesy,Andrew Jacob Brenner,John de Groot,Nicholas Arthur Butowski,Leor Zach,Jian Li Campian,Benjamin M. Ellingson,Laurence S. Freedman,Yael Chava Cohen,Noa Lowenton‐Spier,Tamar Rachmilewitz Minei,Shifra Fain Shmueli,GLOBE Study Investigators,Patrick Yung Wen,Nicholas George Avgeropoulos,Joseph T. Beck,Tara L. Benkers,Felix Bokstein,Andrew Brenner,Eric Burton
出处
期刊:Neuro-oncology [Oxford University Press]
卷期号:22 (5): 705-717 被引量:74
标识
DOI:10.1093/neuonc/noz232
摘要

BACKGROUND: Ofranergene obadenovec (VB-111) is an anticancer viral therapy that demonstrated in a phase II study a survival benefit for patients with recurrent glioblastoma (rGBM) who were primed with VB-111 monotherapy that was continued after progression with concomitant bevacizumab. METHODS: This pivotal phase III randomized, controlled trial compared the efficacy and safety of upfront combination of VB-111 and bevacizumab versus bevacizumab monotherapy. Patients were randomized 1:1 to receive VB-111 1013 viral particles every 8 weeks in combination with bevacizumab 10 mg/kg every 2 weeks (combination arm) or bevacizumab monotherapy (control arm). The primary endpoint was overall survival (OS), and secondary endpoints were objective response rate (ORR) by Response Assessment in Neuro-Oncology (RANO) criteria and progression-free survival (PFS). RESULTS: Enrolled were 256 patients at 57 sites. Median exposure to VB-111 was 4 months. The study did not meet its primary or secondary goals. Median OS was 6.8 versus 7.9 months in the combination versus control arm (hazard ratio, 1.20; 95% CI: 0.91-1.59; P = 0.19) and ORR was 27.3% versus 21.9% (P = 0.26). A higher rate of grades 3-5 adverse events was reported in the combination arm (67% vs 40%), mainly attributed to a higher rate of CNS and flu-like/fever events. Trends for improved survival with combination treatment were seen in the subgroup of patients with smaller tumors and in patients who had a posttreatment febrile reaction. CONCLUSIONS: In this study, upfront concomitant administration of VB-111 and bevacizumab failed to improve outcomes in rGBM. Change of treatment regimen, with the lack of VB-111 monotherapy priming, may explain the differences from the favorable phase II results. CLINICAL TRIALS REGISTRATION: NCT02511405.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
Mole发布了新的文献求助10
11秒前
46秒前
47秒前
47秒前
Lucas的应助被Mole采纳,获得10
1分钟前
xiaojiu完成签到,获得积分10
1分钟前
1分钟前
1分钟前
spinon发布了新的文献求助20
1分钟前
Mole发布了新的文献求助10
1分钟前
Mole完成签到,获得积分10
1分钟前
1分钟前
Dryang完成签到 ,获得积分10
1分钟前
窗窗窗雨完成签到,获得积分10
1分钟前
amiee发布了新的文献求助10
1分钟前
蝎子莱莱xth完成签到,获得积分0
2分钟前
超帅的幻枫完成签到,获得积分10
2分钟前
氢锂钠钾铷铯钫完成签到,获得积分10
2分钟前
东风完成签到,获得积分10
2分钟前
fjmelite完成签到 ,获得积分10
2分钟前
完美世界的应助被choup53采纳,获得10
2分钟前
Square完成签到,获得积分10
2分钟前
如意的鼠标完成签到 ,获得积分10
2分钟前
lzq671完成签到 ,获得积分10
2分钟前
在水一方的应助被科研通管家采纳,获得10
2分钟前
ding的应助被科研通管家采纳,获得10
2分钟前
2分钟前
faust0052完成签到 ,获得积分10
2分钟前
浚稚完成签到 ,获得积分0
3分钟前
wood完成签到,获得积分10
3分钟前
aiyouwei完成签到,获得积分10
3分钟前
乐观的素阴完成签到 ,获得积分10
3分钟前
自由文博完成签到 ,获得积分10
4分钟前
幸福海之完成签到,获得积分10
4分钟前
4分钟前
choup53发布了新的文献求助10
4分钟前
腼腆的夏蓉完成签到,获得积分10
5分钟前
寻找组织完成签到,获得积分10
5分钟前
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190226
求助须知:如何正确求助?哪些是违规求助? 9577371
关于积分的说明 21852394
捐赠科研通 7788780
什么是DOI,文献DOI怎么找? 3436315
关于科研通互助平台的介绍 2560109
邀请新用户注册赠送积分活动 2482945